• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Propensity of fluoroquinolones with different moieties at position 8 to cause resistance development in clinical isolates of Streptococcus pneumoniae.8位带有不同基团的氟喹诺酮类药物在肺炎链球菌临床分离株中引起耐药性产生的倾向。
Antimicrob Agents Chemother. 2001 Sep;45(9):2666-7. doi: 10.1128/AAC.45.9.2666-2667.2001.
2
Determining the frequency of resistance of Streptococcus pneumoniae to ciprofloxacin, levofloxacin, trovafloxacin, grepafloxacin, and gemifloxacin.测定肺炎链球菌对环丙沙星、左氧氟沙星、曲伐沙星、格帕沙星和吉米沙星的耐药频率。
Eur J Clin Microbiol Infect Dis. 2001 Dec;20(12):883-5. doi: 10.1007/s10096-001-0636-6.
3
Single- and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae.肺炎链球菌中吉米沙星与曲伐沙星、环丙沙星、加替沙星和莫西沙星的单步及多步耐药性选择研究
J Antimicrob Chemother. 2001 Sep;48(3):365-74. doi: 10.1093/jac/48.3.365.
4
Comparative activities of ciprofloxacin, clinafloxacin, gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against epidemiologically defined Acinetobacter baumannii strains.环丙沙星、克林沙星、加替沙星、吉米沙星、左氧氟沙星、莫西沙星和曲伐沙星对根据流行病学定义的鲍曼不动杆菌菌株的比较活性。
Antimicrob Agents Chemother. 2000 Aug;44(8):2211-3. doi: 10.1128/AAC.44.8.2211-2213.2000.
5
Comparative in vitro activity of gemifloxacin to other fluoroquinolones and non-quinolone agents against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the United States in 1999-2000.1999 - 2000年美国吉米沙星与其他氟喹诺酮类及非喹诺酮类药物对肺炎链球菌、流感嗜血杆菌和卡他莫拉菌的体外活性比较
Int J Antimicrob Agents. 2002 Jan;19(1):33-7. doi: 10.1016/s0924-8579(01)00431-9.
6
Ex vivo serum activity (killing rates) after gemifloxacin 320 mg versus trovafloxacin 200 mg single doses against ciprofloxacin-susceptible and -resistant Streptococcus pneumoniae.320毫克吉米沙星与200毫克曲伐沙星单剂量给药后，对环丙沙星敏感和耐药的肺炎链球菌的体外血清活性（杀菌率）。
Int J Antimicrob Agents. 2002 Aug;20(2):144-6. doi: 10.1016/s0924-8579(02)00119-x.
7
In vitro susceptibility to gemifloxacin and trovafloxacin of Streptococcus pneumoniae strains exhibiting decreased susceptibility to ciprofloxacin.对环丙沙星敏感性降低的肺炎链球菌菌株对吉米沙星和曲伐沙星的体外敏感性
Eur J Clin Microbiol Infect Dis. 2000 Feb;19(2):137-9. doi: 10.1007/s100960050446.
8
Comparative in vitro potency of gemifloxacin and fluoroquinolones against recent European clinical isolates from a global surveillance study.吉米沙星与氟喹诺酮类药物对全球监测研究中近期欧洲临床分离株的体外比较效力
Eur J Clin Microbiol Infect Dis. 2001 Nov;20(11):814-9. doi: 10.1007/s100960100604.
9
Efficacy and pharmacodynamics of gemifloxacin versus levofloxacin in guinea pig pneumococcal pneumonia induced by strains with decreased ciprofloxacin susceptibility.吉米沙星与左氧氟沙星对环丙沙星敏感性降低菌株所致豚鼠肺炎球菌肺炎的疗效及药效学研究
Int J Antimicrob Agents. 2003 Jun;21(6):568-73. doi: 10.1016/s0924-8579(03)00059-1.
10
Antistaphylococcal and antistreptococcal killing kinetics of ciprofloxacin, ofloxacin, sparfloxacin, and trovafloxacin.环丙沙星、氧氟沙星、司帕沙星和曲伐沙星对葡萄球菌和链球菌的杀菌动力学
Eur J Clin Microbiol Infect Dis. 1998 Nov;17(11):816-9. doi: 10.1007/s100960050199.

引用本文的文献

1
Guide to selection of fluoroquinolones in patients with lower respiratory tract infections.下呼吸道感染患者氟喹诺酮类药物的选择指南。
Drugs. 2005;65(7):949-91. doi: 10.2165/00003495-200565070-00004.
2
Mutant selection window in levofloxacin and moxifloxacin treatments of experimental pneumococcal pneumonia in a rabbit model of human therapy.左氧氟沙星和莫西沙星治疗人用治疗兔实验性肺炎球菌肺炎的突变选择窗
Antimicrob Agents Chemother. 2004 May;48(5):1699-707. doi: 10.1128/AAC.48.5.1699-1707.2004.
3
In vitro antibacterial activity and pharmacodynamics of new quinolones.新型喹诺酮类药物的体外抗菌活性及药效学
Eur J Clin Microbiol Infect Dis. 2003 Apr;22(4):203-21. doi: 10.1007/s10096-003-0907-5. Epub 2003 Apr 1.
4
Mutant prevention concentration of gemifloxacin for clinical isolates of Streptococcus pneumoniae.吉米沙星对肺炎链球菌临床分离株的突变预防浓度
Antimicrob Agents Chemother. 2003 Jan;47(1):440-1. doi: 10.1128/AAC.47.1.440-441.2003.

本文引用的文献

1
In vitro development of resistance to six quinolones in Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus.肺炎链球菌、化脓性链球菌和金黄色葡萄球菌对六种喹诺酮类药物的体外耐药性发展情况。
Antimicrob Agents Chemother. 2001 Mar;45(3):938-42. doi: 10.1128/AAC.45.3.938-942.2001.
2
Gatifloxacin activity against quinolone-resistant gyrase: allele-specific enhancement of bacteriostatic and bactericidal activities by the C-8-methoxy group.加替沙星对喹诺酮耐药性螺旋酶的活性：C-8-甲氧基对抑菌和杀菌活性的等位基因特异性增强作用。
Antimicrob Agents Chemother. 1999 Dec;43(12):2969-74. doi: 10.1128/AAC.43.12.2969.
3
Fluoroquinolone action against clinical isolates of Mycobacterium tuberculosis: effects of a C-8 methoxyl group on survival in liquid media and in human macrophages.氟喹诺酮对结核分枝杆菌临床分离株的作用：C-8甲氧基对在液体培养基和人巨噬细胞中存活的影响。
Antimicrob Agents Chemother. 1999 Mar;43(3):661-6. doi: 10.1128/AAC.43.3.661.
4
Fluoroquinolone action against mycobacteria: effects of C-8 substituents on growth, survival, and resistance.氟喹诺酮对分枝杆菌的作用：C-8取代基对生长、存活及耐药性的影响
Antimicrob Agents Chemother. 1998 Nov;42(11):2978-84. doi: 10.1128/AAC.42.11.2978.
5
Killing of Staphylococcus aureus by C-8-methoxy fluoroquinolones.C-8-甲氧基氟喹诺酮类药物对金黄色葡萄球菌的杀灭作用
Antimicrob Agents Chemother. 1998 Apr;42(4):956-8. doi: 10.1128/AAC.42.4.956.
6
DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance.氟喹诺酮类药物的DNA拓扑异构酶靶点：一种避免细菌耐药性的策略。
Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13991-6. doi: 10.1073/pnas.94.25.13991.
7
Improved bactericidal activity of Q-35 against quinolone-resistant staphylococci.Q-35对喹诺酮耐药葡萄球菌的杀菌活性增强。
Antimicrob Agents Chemother. 1995 Jul;39(7):1522-5. doi: 10.1128/AAC.39.7.1522.
8
Contribution of the C-8 substituent of DU-6859a, a new potent fluoroquinolone, to its activity against DNA gyrase mutants of Pseudomonas aeruginosa.新型强效氟喹诺酮类药物DU-6859a的C-8取代基对其抗铜绿假单胞菌DNA旋转酶突变体活性的贡献。
Antimicrob Agents Chemother. 1995 Jul;39(7):1467-71. doi: 10.1128/AAC.39.7.1467.

Propensity of fluoroquinolones with different moieties at position 8 to cause resistance development in clinical isolates of Streptococcus pneumoniae.

作者信息

Schmitz F J, Boos M, Mayer S, Hafner D, Jagusch H, Verhoef J, Fluit A C

出版信息

Antimicrob Agents Chemother. 2001 Sep;45(9):2666-7. doi: 10.1128/AAC.45.9.2666-2667.2001.

DOI:10.1128/AAC.45.9.2666-2667.2001
PMID:11523528
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC90713/
Abstract
摘要